Anti-NASH Drug Development Hitches a Lift on PPAR Agonism

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH). NASH is a severe condition characterized by steatosis and concomitant liver inflammation and fibrosis, for which no dru...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cells
Autori principali: Boeckmans, Joost, Natale, Alessandra, Rombaut, Matthias, Buyl, Karolien, Rogiers, Vera, De Kock, Joery, Vanhaecke, Tamara, Rodrigues, Robim M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2019
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016963/
https://ncbi.nlm.nih.gov/pubmed/31877771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010037
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi